ClinicalTrials.gg
RecruitingNCT07487844Updated Nov 18, 2026

Pulsed Electric Field Ablation for Metastatic Breast Cancer

An interventional study of Pulsed Electric Field (PEF) System and Questionnaires in Metastatic Breast Cancer and Breast Cancer, sponsored by University of California, San Francisco. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of California, San Francisco · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Nov 18, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 62 studies in Breast Neoplasms by University of California, San Francisco — 11 open to participants now, 16 under way, 1 of them phase 3. Breast Neoplasms · University of California, San Francisco.

Planned enrollment
38th of 49
20 · median 38
Started
2026
with 3 others
No phase
23 of 62
4 open now
Primary completion
2028-12
later than 8 of 15 live
Registered
59th of 62
by date

Among the 62 studies in Breast Neoplasms by University of California, San Francisco, this one is the 38th largest by planned enrollment of the 49 interventional ones that give a count, is one of 4 that started in 2026, is one of 23 with no phase, reaches primary completion later than 8 of the 15 other live ones, and was the 59th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

11 of the 62 studies in Breast Neoplasms by University of California, San Francisco are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Breast Neoplasms by University of California, San Francisco, or all of them as a file.
02

Study summary

This is a phase I trial of the safety of image-guided pulsed electric field (PEF) ablation for the locoregional treatment of superficial soft tissue lesions in adults with metastatic breast cancer using the AliyaTM Pulsed Electric Field System.

Read the detailed description

PRIMARY OBJECTIVE:

I. To assess the safety of PEF for locoregional treatment of soft tissue metastatic breast cancer lesions.

SECONDARY OBJECTIVE:

I. To assess the effect of PEF on patient-reported symptoms and quality of life.

II. To assess the feasibility of performing PEF for superficial soft tissue metastases.

EXPLORATORY OBJECTIVE:

I. To explore blood-based biomarker responses to PEF.

II. To explore the efficacy of PEF in treating locoregional disease, as well as its effect on untreated lesions.

OUTLINE:

Participants will receive a single treatment of PEF ablation delivered to up to 3 soft metastatic breast cancer lesion(s). After the treatment, participants are followed at Day 0, week 2, week 4, and up to 1 year post ablation.

03

Conditions studied

  • Metastatic Breast Cancer
  • Breast Cancer

Browse trials for

Keywords

  • Image Guided Ablation
  • Tumor Ablation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must have or cytologically confirmed breast cancer.
  2. Confirmed documented soft tissue involvement via imaging or , with at least one with a cutaneous and/or subcutaneous component that is at least 1 cm in size but no greater than 5 cm in size and that can be safely accessed under image guidance. Up to 3 lesions that meet these criteria may be treated with PEF ablation therapy.
  3. There are no limits on the amount of prior or concurrent anti-cancer therapies, but patients must be medically able (in the opinion of referring provider and treating investigator) to withhold their systemic therapy for breast cancer one week before the PEF ablation and for 2 weeks after the procedure.
  4. Age ≥18 years
  5. (ECOG) performance status ≤ 2.
  6. Adequate Bone Marrow Function:

    1. ≥1,500/microliter (mcL).
    2. ≥100,000/mcL.
  7. Not on or able to withhold anticoagulation or antiplatelet therapy per Society of Interventional Radiology periprocedural guideline.
  8. (HIV)-infected individuals on effective anti-retroviral therapy with undetectable viral load within 6 months (as documented in the medical record) are eligible for this trial.
  9. For participants with evidence of chronic virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy (as documented in the medical record), if indicated.
  10. Individuals with a history of virus (HCV) infection must have been treated and cured. For individuals with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load (as documented in the medical record).
  11. Individuals with a prior or concurrent whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are eligible for this trial.
  12. The effects of pulsed electric field on the developing human fetus are unknown. For this reason individuals of must agree to use adequate : (e.g., hormonal or barrier method of birth control; abstinence, etc.) for the duration of study participation and for 4 weeks after last administration of study treatment. Should a study participant become pregnant or suspect pregnancy while participating in this study, they should inform their treating physician immediately.

Exclusion criteria

Exclusion Criteria:

  1. Has not recovered from adverse events due to prior/concurrent systemic anti-cancer therapy to ≤ Grade 2 ( v5.0) or baseline (other than alopecia).
  2. Individuals with pacemakers or other electronic implant devices.
  3. Individuals who are unable or unwilling, or with medical , to undergo moderate sedation and local anesthesia.
  4. Pregnant individuals are excluded from this study because there is unknown risk of PEF on fetus.
  5. Breastfeeding/chestfeeding individuals are excluded from this study because there is unknown risk on nursing infants; breastfeeding/chestfeeding should be discontinued prior to initiating study treatment.
  6. Individuals with any condition or social circumstance that, in the opinion of the treating investigator, would impair the participant's ability to comply with study procedures.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Image-Guided Pulsed Electric Field (PEF) Ablation

    Participants undergo a single treatment of PEF ablation delivered to up to 3 soft tissue metastatic breast cancer lesion(s). Ablation parameters, immediate adverse events, and post-ablation imaging will be collected during the ablation treatment.

    Device: Pulsed Electric Field (PEF) System · Behavioral: Questionnaires · Procedure: Tumor Ablation

Interventions

  • DevicePulsed Electric Field (PEF) System

    Pulsed electric field (PEF) delivers short, high frequency electrical pulses that are intended to shrink or destroy tumors

    Also known as: PEF, Aliya™ PEF System

  • BehavioralQuestionnaires

    Participants will complete health related, quality of life questionnaires

  • ProcedureTumor Ablation

    Undergo ablation via PEF

    Also known as: Ablation

06

What researchers measure

Primary outcomes

  1. Proportion of participants with treatment-emergent adverse events

    Proportion of participants who experience adverse event from the Pulsed Electric Field (PEF) ablation treatment. Standard deviation and 95% confidence intervals will be reported.

    Time frame: Up to 4 weeks

Secondary outcomes

  1. Mean change of score on European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Breast Cancer Module (EORTC QLQ BR-23)

    EORTC QLQ-BR23 incorporates five multi-item scales to assess body image, sexual functioning, systemic therapy side effects, breast symptoms, and arm symptoms. In addition, single items assess sexual enjoyment, future perspective and being upset by hair loss. All of the scales and single-item measures range in score from 0 to 100. The mean and standard deviation of the change in EORTC QLQ-BR23 scores, along with the 95% confidence interval, will be reported.

    Time frame: Up to 4 weeks

  2. Mean change of score on EuroQol five-dimensional Questionnaire (EQ-5D)

    EQ-5D is a standardized instrument for measuring generic health status. The health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The respondents self-rate their level of severity for each dimension by selecting one of the following responses: no problems (0), slight problems (1), mild problems (2), moderate problems (3), or severe problems (4) with a particular dimension. The mean and standard deviation of the change in EQ-5D scores, along with the 95% confidence interval, will be reported.

    Time frame: Up to 4 weeks

  3. Mean technical success rate of Pulsed Electric Field (PEF) ablation

    Immediately after PEF ablation, the technical success rate and any procedural technical challenges will be recorded. Mean, standard deviation of technical success rate for PEF ablation and 95% confidence will be reported.

    Time frame: Up to 1 day

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2028, 30 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 30 months is close to that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Aug 2028 → Dec 2028 and completion Aug 2028 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2026
First posted
Mar 23, 2026
StartActual
Jun 29, 2026
Primary completionEst.
Dec 31, 2028was Aug 2028
CompletionEst.
Dec 31, 2028was Aug 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 1, 2028→Dec 31, 2028
Nov 18, 2026
Study completion
Aug 1, 2028→Dec 31, 2028
Nov 18, 2026
Contact
Study contact changed: m•••@ucsf.edu · •••3222→S•••@ucsf.edu · •••1300; added X•••@ucsf.edu · •••1300. See the current contact
Nov 18, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • University of California San Francisco · San Francisco, United StatesContact M•••@ucsf.edu · •••3222→S•••@ucsf.edu · •••1300Contact c•••@ucsf.edu→X•••@ucsf.edu · •••1300
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Primary completion Aug 1, 2028→Dec 31, 2028
    Study completion Aug 1, 2028→Dec 31, 2028
    Contact Study contact changed: m•••@ucsf.edu · •••3222→S•••@ucsf.edu · •••1300; added X•••@ucsf.edu · •••1300. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University of California San Francisco · San Francisco, United StatesContact M•••@ucsf.edu · •••3222→S•••@ucsf.edu · •••1300Contact c•••@ucsf.edu→X•••@ucsf.edu · •••1300
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07487844
Collaborators
Galvanize Therapeutics, Inc., Society of Interventional Radiology Foundation
Responsible party
Sponsor
First posted
Mar 23, 2026
Start date
Jun 29, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Sophia Millet
Contact
Sophia.Millet@ucsf.edu
415-353-1300
Xiao Wu, MD
Contact
Xiao.Wu@ucsf.edu
415-353-1300
Ryan Kohlbrenner, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion